Literature DB >> 11437679

Schönlein-henoch purpura in children and adults: diagnosis, pathophysiology and management.

G Rostoker1.   

Abstract

Schönlein-Henoch syndrome is a form of systemic small-vessel vasculitis, characterised by vascular and/or mesangial immunoglobulin A1 deposits. The main clinical manifestations are vascular purpura, predominating on the lower limbs, and articular, gastrointestinal and renal symptoms. Pulmonary, cardiac, genital and neurological symptoms have also be observed. The syndrome usually affects children, whereas it is rare in adults. The frequency of renal involvement varies between individual studies (from 20 to 100%). Renal manifestations are usually mild and transient, although chronic nephropathies may occur. Overall, an estimated 2% of children with Schönlein-Henoch purpura progress to renal failure and up to 20% of children with nephritis treated in specialised centres require haemodialysis. The renal prognosis appears to be worse in adults. Aetiological investigations are required, as a triggering factor is found in approximately half the patients (e.g. viral, bacterial and parasitic infections, drugs, toxins, systemic diseases and cancer). Dapsone has beneficial effects on cutaneous, gastrointestinal and articular manifestations in adults, especially those with chronic forms. Corticosteroids may be useful for refractory abdominal pain. Methylprednisolone pulse therapy, immunosuppressive drugs (e.g. cyclophosphamide and azathioprine), plasma exchange and polyclonal immunoglobulin therapy are beneficial in very rare life-threatening forms of the disease and in rare instances where renal function is compromised.

Entities:  

Mesh:

Year:  2001        PMID: 11437679     DOI: 10.2165/00063030-200115020-00004

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  23 in total

Review 1.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 2.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

3.  Necrosis of mesenteric lymph nodes in Henoch-Schönlein purpura.

Authors:  Pietro Ferrara; Donato Rigante; Antonio Leone; Claudia Orchi; Nadia Puma; Aurora Rossodivita; Emanuela Sacco; Pio Liberatore; Maria Elena Laino; Achille Stabile
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

4.  Thrombosis and priapism in a patient with Henoch-Schonlein purpura.

Authors:  Ismail Sari; Servet Akar; Mustafa Secil; Merih Birlik; Aykut Kefi; Fatos Onen; Ilhan Celebi; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-11-10       Impact factor: 2.631

5.  [Henoch-Schönlein purpura : most frequent form of vasculitis in childhood and adolescence].

Authors:  T Hospach; H-I Huppertz
Journal:  Z Rheumatol       Date:  2011-12       Impact factor: 1.372

6.  Predictors of outcome in Henoch-Schönlein nephritis.

Authors:  Stella Edström Halling; Magnus P Söderberg; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2010-02-20       Impact factor: 3.714

7.  Henoch-Schönlein purpura in children: limited benefit of corticosteroids.

Authors:  Joel Bluman; Ran D Goldman
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

8.  Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura.

Authors:  Pamela F Weiss; Andrew J Klink; Russell Localio; Matt Hall; Kari Hexem; Jon M Burnham; Ron Keren; Chris Feudtner
Journal:  Pediatrics       Date:  2010-09-20       Impact factor: 7.124

9.  Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura.

Authors:  Donato Rigante; Marcello Candelli; Gilda Federico; Francesco Bartolozzi; Maria Grazia Porri; Achille Stabile
Journal:  Rheumatol Int       Date:  2004-03-06       Impact factor: 2.631

Review 10.  Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.

Authors:  Pamela F Weiss; James A Feinstein; Xianqun Luan; Jon M Burnham; Chris Feudtner
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.